-
公开(公告)号：US08575113B2
公开(公告)日：2013-11-05
申请号：US12825197
申请日：2010-06-28
申请人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James B. Jaquith , Alain Laurent , Delphine Labit
发明人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James B. Jaquith , Alain Laurent , Delphine Labit
CPC分类号： C07D207/09 , C07K5/06026 , C07K5/06034 , C07K5/06069
摘要： The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.
摘要翻译： 本发明涉及由式I表示的吡咯烷化合物的异构体，对映异构体，非对映异构体或互变异构体：其中取代基R1，R1a，R2，R2a，R3，A和Q如本文所定义; 或其前药或其盐，并且其结合IAP BIR结构域。 特别地，这些化合物可用于治疗增殖性疾病如癌症。
-
公开(公告)号：US20060264379A1
公开(公告)日：2006-11-23
申请号：US11434166
申请日：2006-05-16
申请人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
发明人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
CPC分类号： C07D207/09 , C07K5/06026 , C07K5/06034 , C07K5/06069
摘要： The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer
摘要翻译： 本发明涉及由式I表示的吡咯烷化合物的异构体，对映体，非对映异构体或互变异构体：其中取代基R 1，R 1a， R 2，R 2，R 3，A和Q在本文中定义; 或其前药或其盐，并且其结合IAP BIR结构域。 特别地，这些化合物可用于治疗增殖性疾病如癌症
-
公开(公告)号：US20100292269A1
公开(公告)日：2010-11-18
申请号：US12825197
申请日：2010-06-28
申请人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
发明人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
IPC分类号： A61K31/4725 , C12N5/02 , A61K31/4709 , A61K31/4439 , A61K31/4178 , A61K31/40
CPC分类号： C07D207/09 , C07K5/06026 , C07K5/06034 , C07K5/06069
摘要： The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer
摘要翻译： 本发明涉及由式I表示的吡咯烷化合物的异构体，对映异构体，非对映异构体或互变异构体：其中取代基R1，R1a，R2，R2a，R3，A和Q如本文所定义; 或其前药或其盐，并且其结合IAP BIR结构域。 特别地，这些化合物可用于治疗增殖性疾病如癌症
-
公开(公告)号：US07772177B2
公开(公告)日：2010-08-10
申请号：US11434166
申请日：2006-05-16
申请人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
发明人： Scott Jarvis , Alain Boudreault , Patrick Bureau , James Jaquith , Alain Laurent , Delphine Labit
IPC分类号： C07K5/06
CPC分类号： C07D207/09 , C07K5/06026 , C07K5/06034 , C07K5/06069
摘要： The present invention is directed towards an isomer, an enantiomer, a diastereoisomer, or a tautomer of a pyrrolidine compound represented by Formula I: in which the substituents R1, R1a, R2, R2a, R3, A and Q are defined herein; or a prodrug, or a salt thereof, and which bind to IAP BIR domains. In particular, the compounds are useful in treating proliferative disorders such as cancer.
摘要翻译： 本发明涉及由式I表示的吡咯烷化合物的异构体，对映异构体，非对映异构体或互变异构体：其中取代基R1，R1a，R2，R2a，R3，A和Q如本文所定义; 或其前药或其盐，并且其结合IAP BIR结构域。 特别地，这些化合物可用于治疗增殖性疾病如癌症。
-
公开(公告)号：US07645741B2
公开(公告)日：2010-01-12
申请号：US11979280
申请日：2007-11-01
IPC分类号： A61K38/08 , A61K39/395 , A61P35/00 , C07K7/06 , C12Q1/02
CPC分类号： C07K5/0812 , A61K31/40 , A61K31/4025 , A61K38/00 , A61K38/08 , A61K38/1761 , C07D207/14 , C07D207/16 , C07K5/0806 , C07K5/0808 , C07K5/081 , C07K7/06
摘要： Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I or II or a salt thereof, in which R1, R2, R3, R100, R200, R300, A, A1, BG, Q and Q1 are substituents described herein. Also disclosed is the use of compounds of Formula I and II to treat proliferative disorders such as cancer.
摘要翻译： 公开了由式I或II表示的化合物或其盐的异构体，对映体，非对映异构体或互变异构体，其中R1，R2，R3，R100，R200，R300，A，A1，BG，Q和Q1是描述的取代基 这里。 还公开了使用式I和II的化合物来治疗增殖性疾病如癌症。
-
公开(公告)号：US08163792B2
公开(公告)日：2012-04-24
申请号：US12301213
申请日：2007-05-16
申请人： Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
发明人： Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
IPC分类号： C07D207/09 , A61K31/4025
CPC分类号： G01N33/57484 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D409/14 , C07D487/06 , C07D493/10 , C07K5/022 , C07K5/06026 , C07K5/06191 , G01N2333/4703 , G01N2333/70596 , G01N2500/02
摘要： Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
摘要翻译： 本文公开了由式I表示的化合物的异构体，对映异构体，非对映异构体或互变异构体：或前药或药学上可接受的盐，或用可检测标记或其亲和标签标记; 其中R1，R1a，R100，R100a，R2，R200，W，B和W1在本文中定义。 还公开了使用式I化合物治疗增殖性疾病如癌症的方法。
-
公开(公告)号：US20070219140A1
公开(公告)日：2007-09-20
申请号：US11607964
申请日：2006-12-04
申请人： Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人： Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号： A61K38/06 , A61K38/05 , A61K38/04 , C07K5/08 , C07K5/06 , C07D403/14 , A61K31/4025
CPC分类号： C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要： Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substitutents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
摘要翻译： 公开了由式I表示的化合物或其盐的异构体，对映异构体，非对映异构体或互变异构体，其中R 1，R 2，R 100， A，A，B，B，B，B，B，B，B，B，B， 是描述的替代品。 还公开了使用式1的化合物来治疗增殖性疾病。
-
公开(公告)号：US08648094B2
公开(公告)日：2014-02-11
申请号：US13425542
申请日：2012-03-21
申请人： Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
发明人： Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
IPC分类号： A61K31/4025 , A61K31/444 , C07D401/12 , C07D403/12
CPC分类号： G01N33/57484 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D409/14 , C07D487/06 , C07D493/10 , C07K5/022 , C07K5/06026 , C07K5/06191 , G01N2333/4703 , G01N2333/70596 , G01N2500/02
摘要： Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
摘要翻译： 本文公开了由式I表示的化合物的异构体，对映异构体，非对映异构体或互变异构体：或前药或药学上可接受的盐，或用可检测标记或其亲和标签标记; 其中R1，R1a，R100，R100a，R2，R200，W，B和W1在本文中定义。 还公开了使用式I化合物治疗增殖性疾病如癌症的方法。
-
公开(公告)号：US08063095B2
公开(公告)日：2011-11-22
申请号：US11607964
申请日：2006-12-04
申请人： Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
发明人： Alain Laurent , Kim Hewitt , Stephen Morris , Patrick Bureau , Alain Boudreault , Scott Jarvis , James Jaquith
IPC分类号： A61K31/4025 , C07D207/09
CPC分类号： C07D207/16 , A61K38/00 , C07D403/06 , C07D403/14 , C07K5/0806
摘要： Disclosed is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a salt thereof, in which R1, R2, R100, R200, A, A1, B, B1, BG, n, Q and Q1 are substituents described. Also disclosed is the use of compounds of Formula 1 to treat proliferative disorders.
摘要翻译： 公开了由式I表示的化合物或其盐的异构体，对映异构体，非对映异构体或互变异构体，其中R1，R2，R100，R200，A，A1，B，B1，BG，n，Q和Q1是取代基 描述。 还公开了使用式1的化合物来治疗增殖性疾病。
-
公开(公告)号：US20120195915A1
公开(公告)日：2012-08-02
申请号：US13425542
申请日：2012-03-21
申请人： Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
发明人： Alain Laurent , Scott Jarvis , Patrick Bureau , Alain Boudreault , James Jaquith
CPC分类号： G01N33/57484 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D409/14 , C07D487/06 , C07D493/10 , C07K5/022 , C07K5/06026 , C07K5/06191 , G01N2333/4703 , G01N2333/70596 , G01N2500/02
摘要： Disclosed herein is an isomer, enantiomer, diastereoisomer or tautomer of a compound represented by Formula I: or a prodrug, or a pharmaceutically acceptable salt, or labeled with a detectable label or an affinity tag thereof; wherein R1, R1a, R100, R100a, R2, R200, W, B, and W1 are defined herein. Also disclosed are methods of using compounds of Formula I to treat proliferative disorders such as cancer.
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.069 秒)
